痛风患者并发肾功能不全的危险因素分析-现代医学

痛风患者并发肾功能不全的危险因素分析

单位：江苏省扬中市人民医院肾脏科, 江苏扬中 212200

分类号：R589.7

出版年·卷·期（页码）：2018·46·第八期（858-862）

摘要：

目的：本研究将分析痛风患者并发肾功能不全的危险因素，为患者的自我防治及临床治疗提供一定的借鉴。方法：回顾性分析我院符合纳入标准的126例痛风患者为研究对象。将其分成肾功能正常组及肾功能不全组。分析两组患者的相关并发症、实验室数据、治疗选择的药物和人口统计学等资料。结果：入组患者中52例痛风患者并发肾功能不全（41.27%）；相较于肾功能正常组患者，肾功能不全组患者使用NSAIDs的病例数显著升高，CRP及血肌酐水平显著增加，血红蛋白则显著降低（P<0.05）；肾功能不全组患者男性比例、年龄、并发缺血性心脑血管病及高血压病的例数显著高于肾功能正常组患者（P<0.05）；缺血性心脑血管病、高血压病、发病年龄、关节症状、血肌酐水平、NSAIDs治疗及CRP水平与痛风患者并发肾功能不全表现为正相关性（P<0.05）；尿PH及血红蛋白水平与痛风患者并发肾功能不全表现为负相关性（P<0.05）；服用NSAIDs、发病年龄及尿PH值是痛风患者并发肾功能不全的高危因素（OR：5.987、0.839、0.286、1.086，P<0.05）。结论：对于痛风并发肾功能不全患者，应及时使用降尿酸药物和碱化尿液干预，以达到预防和减缓肾功能不全并发症出现的目的。

Objective:To analysis of the risk factors of renal failure in patients with gout.Methods:126 patients undergoing gout in our rheumatology department from May 2014 to May 2017 were retrospectively analyzed. patients were were divided into renal failure and renal insufficiency group. Their demographic data, clinical manifestations, drugs of treatment, complications and laboratory dates were analyzed. Data were statisticallyanalyzed by SPSS 19.0.Results:The incidence of renal failure was 41.27%. Compared with the normal renal function group, the number of patients with NSAIDs in the renal insufficiency group was significantly higher than that in normal renal function group (P<0.05), and the levels of CRP and serum creatinine were significantly increased (P<0.05), while the level of serum creatinine was significantly decreased in patients with renal insufficiency (P<0.05). The proportion of male, old age, ischemic cardio-cerebrovascular disease and hypertension in renal insufficiency group were significantly higher than those in the normal renal function group (P<0.05). There were positive correlations between renal failure in patients with gout and ischemic cerebrovascular disease, hypertension, age of onset, joint symptoms, serum creatinine level, NSAIDs treatment, CRP were significant (P<0.05); There were negative correlations between renal failure in patients with gout and urinary PH, hemoglobin level were significant (P<0.05); NSAIDs, age of onset and pH of urine were high risk factors for renal failure in gout patients (OR:5.987,0.839,0.286,1.086,P<0.05). Conclusion:The age of onset was a high risk factor for the disease. Therefore, it was necessary to pay attention to the elderly at aearly stage. We should treat uric acid timely to reduce the level of blood uric acid in order to prevent and slow down the occurrence of renal failure complications.

参考文献：

[1] FRAMPTON J E.Febuxostat:a review of its use in the treatment of hyperuricaemia in patients with gout[J].Drugs,2015,75(4):427-438.
[2] DIRKEN-HEUKENSFELDT K J,TEUNISSEN T A,van de LISDONK H,et al.Clinical features of women with gout arthritis:A systematic review[J].Clni Rheumatol,2010,29(6):575-582.
[3] 武东,赵金霞,孙琳,等.痛风炎症机制的研究进展[J].中华风湿病学杂志,2014,18(2):128-130.
[4] TSURUTA Y,MOCHIZUKI T,MORIYAMA T,et al.Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease[J].Clin Rheumatol,2014,33(11):1643-1648.
[5] KATAOKA H,YANG K,ROCK K,et al.The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury induced inflammation in the liver and lung[J].Eur J Pharmacol,2015,746:174-179.
[6] 张冰清,张昀,曾学军.痛风和高尿酸血症的遗传学背景[J].中华风湿病学杂志,2015,19(1):61-63.
[7] 中华医学会.临床诊疗指南风湿病分册[M].北京:人民卫生出版社,2005:123.
[8] 中华医学会风湿病学分会.原发性痛风诊断和治疗指南[J].中华风湿病学杂志,2011,15(6):410-413.
[9] 庄丽华,胡家才,吴昊.中西医结合治疗急性痛风性关节炎疗效观察[J].微循环学杂志,2014,24(3):18-20.
[10] 黄刚,叶一萍.金匮肾气丸治疗痛风性肾病疗效评价[J].中华中医药学刊,2016,8(11):2808-2810.
[11] 伊世华,隋淑梅,王新伟,等.肾康降酸颗粒治疗痛风性肾病的临床研究[J].中国中医基础医学杂志,2016,8(6):816-817,840.
[12] JR S H,SUNDY J S,TERKELTAUB R,et al.Rilonacept(interleukin-1 trap)in the prevention of acute gout flares during initiation of urate-lowering therapy:results of a phase Ⅱ randomized,double-blind,placebo-controlled trial[J].Arthritis Rheumatology,2014,64(3):876-884.
[13] 王仁朔.体检人群高尿酸血症患病情况及与尿pH值相关性分析[J].风湿病与关节炎,2014,3(4):17-18.
[14] CURIEL R V,GUZMAN N J.Challenges associated with the management of gouty arthritis in patients with chronic kidney disease:A systematic review[J].Semin Anhritis Rheum,2012,42(2):166-178.
[15] LEE J,LEE J Y,LEE J H,et al.Visceral fat obesity is highly associated with primary gout in a metabolically obese but normal weighted population:A case control study[J].Arthritis Res Ther,2015,17(1):79.
[16] 牟科媛.痛风性肾病中医治法方药与现代医学病理药理探析[J].辽宁中医药大学学报,2014,16(5):11-13.
[17] EL-ZAWAWY H,MANDELL B F.Managing gout:How is it different in patients with chronic kidney disease[J].Cleve Clin J Med,2010,77(12):919-928.
[18] 傅淑霞,李绍梅,于连英.2014年肾脏疾病临床进展[J].临床荟萃,2015,30(2):161-166.
[19] GANCHEVA R N,KUNDURDJIEV A I,IVANOVA M G,et al.Ultrasonographic measurement of carotid artery resistive index and diastolic function of the heart in gout patients[J].Rheumatol Int,2015,35(8):1369-1375.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录